AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

Property, Plant and Equipment

Property, Plant and Equipment %Chg

Property, Plant and Equipment Common Size

Right-of-Use Assets

Right-of-Use Assets %Chg

Right-of-Use Assets Common Size

Goodwill

Goodwill %Chg

Goodwill Common Size

Intangible Assets

Intangible Assets %Chg

Intangible Assets Common Size

Investments in Associates and Joint Ventures

Investments in Associates and Joint Ventures %Chg

Investments in Associates and Joint Ventures Common Size

Other Investments

Other Investments %Chg

Other Investments Common Size

Derivative Financial Instruments

Derivative Financial Instruments %Chg

Derivative Financial Instruments Common Size

Other Receivables

Other Receivables %Chg

Other Receivables Common Size

Income Tax Receivable

Income Tax Receivable %Chg

Income Tax Receivable Common Size

Deferred Tax Assets

Deferred Tax Assets %Chg

Deferred Tax Assets Common Size

Total Non-Current Assets

Total Non-Current Assets %Chg

Total Non-Current Assets Common Size

Inventories

Inventories %Chg

Inventories Common Size

Trade and Other Receivables

Trade and Other Receivables %Chg

Trade and Other Receivables Common Size

Cash and Cash Equivalents

Cash and Cash Equivalents %Chg

Cash and Cash Equivalents Common Size

Assets Held for Sale

Assets Held for Sale %Chg

Assets Held for Sale Common Size

Total Current Assets

Total Current Assets %Chg

Total Current Assets Common Size

Total Assets

Total Assets %Chg

Total Assets Common Size

Interest-Bearing Loans and Borrowings

Interest-Bearing Loans and Borrowings %Chg

Interest-Bearing Loans and Borrowings Common Size

Lease Liabilities

Lease Liabilities %Chg

Lease Liabilities Common Size

Trade and Other Payables

Trade and Other Payables %Chg

Trade and Other Payables Common Size

Provisions

Provisions %Chg

Provisions Common Size

Income Tax Payable

Income Tax Payable %Chg

Income Tax Payable Common Size

Total Current Liabilities

Total Current Liabilities %Chg

Total Current Liabilities Common Size

Deferred Tax Liabilities

Deferred Tax Liabilities %Chg

Deferred Tax Liabilities Common Size

Retirement Benefit Obligations

Retirement Benefit Obligations %Chg

Retirement Benefit Obligations Common Size

Short-Term Investments

Short-Term Investments %Chg

Short-Term Investments Common Size

Total Cash and Cash Equivalents

Total Cash and Cash Equivalents %Chg

Total Cash and Cash Equivalents Common Size

Accounts Receivable

Accounts Receivable %Chg

Accounts Receivable Common Size

Total Trade Receivables

Total Trade Receivables %Chg

Total Trade Receivables Common Size

Other Current Assets

Other Current Assets %Chg

Other Current Assets Common Size

Net Property, Plant & Equipment

Net Property, Plant & Equipment %Chg

Net Property, Plant & Equipment Common Size

Net Intangible Assets

Net Intangible Assets %Chg

Net Intangible Assets Common Size

Long-Term Investments

Long-Term Investments %Chg

Long-Term Investments Common Size

Other Long-Term Assets

Other Long-Term Assets %Chg

Other Long-Term Assets Common Size

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Assets	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Cash and Cash Equivalents	8,143	7,058	5,230	5,488	4,797	6,916
Cash and Cash Equivalents
Short-Term Investments	39	50	165	166	133	160
Other Investments
Total Cash and Cash Equivalents	8,182	7,108	5,395	5,654	4,930	7,076
Accounts Receivable	14,338	14,168	13,250	12,972	11,879	11,047
Trade and Other Receivables
Total Trade Receivables	14,338	14,168	13,250	12,972	11,879	11,047
Inventories	6,593	6,467	5,884	5,288	5,662	5,667
Inventories
Other Current Assets	827	1,196	1,610	1,913	1,684	1,603
Derivative Financial Instruments
Income Tax Receivable
Intangible Assets
Assets Held for Sale
Total Current Assets	29,940	28,939	26,139	25,827	24,155	25,393
Total Current Assets
Net Property, Plant & Equipment	13,783	13,229	12,303	11,647	11,513	10,833
Property, Plant and Equipment
Right-of-Use Assets
Net Intangible Assets	38,191	37,925	37,550	37,177	39,394	39,426
Intangible Assets
Goodwill	21,219	21,222	21,130	21,025	21,139	21,060
Goodwill
Long-Term Investments	2,286	2,139	1,900	1,900	2,145	1,871
Investments in Associates and Joint Ventures
Other Investments
Other Long-Term Assets	9,037	8,968	7,231	6,459	6,576	5,757
Derivative Financial Instruments
Other Receivables
Income Tax Receivable
Deferred Tax Assets
Total Assets	114,456	112,422	106,253	104,035	104,922	104,340
Total Assets

Liabilities	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Accounts Payable	25,028	23,986	22,544	22,465	21,684	20,463
Trade and Other Payables
Short-Term Debt	6,174	6,492	3,403	2,337	1,253	5,067
Interest-Bearing Loans and Borrowings
Current Portion of Leases	379	361	355	339	317	292
Lease Liabilities
Other Current Liabilities	2,473	2,697	2,827	2,725	2,672	2,744
Derivative Financial Instruments
Provisions
Income Tax Payable
Total Current Liabilities	34,054	33,536	29,129	27,866	25,926	28,566
Total Current Liabilities
Long-Term Debt	24,700	24,714	26,692	26,506	28,887	27,225
Interest-Bearing Loans and Borrowings
Leases	1,379	1,272	1,196	1,113	1,105	949
Lease Liabilities
Other Long-Term Liabilities	8,352	8,090	8,105	7,679	8,199	8,002
Derivative Financial Instruments
Deferred Tax Liabilities
Retirement Benefit Obligations
Provisions
Income Tax Payable
Other Payables
Total Long-Term Liabilities	34,431	34,076	35,993	35,298	38,191	36,176
Total Liabilities	68,485	67,612	65,122	63,164	64,117	64,742
Total Liabilities

Equity	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Common Stock	388	388	388	388	388	388
Share Capital
Additional Paid-in Capital	35,243	35,238	35,233	35,226	35,203	35,199
Share Premium Account
Capital Redemption Reserve
Merger Reserve
Accumulated Other Comprehensive Income	2,044	2,070	2,054	2,012	1,990	2,078
Other Reserves
Retained Earnings	8,213	7,023	3,364	3,160	3,138	1,847
Retained Earnings
Total Common Shareholders' Equity	45,888	44,719	41,039	40,786	40,719	39,512
Capital and Reserves Attributable to Equity Holders of the Parent
Minority Interests and Other	83	91	92	85	86	86
Non-Controlling Interests
Total Shareholders' Equity	45,971	44,810	41,131	40,871	40,805	39,598
Total Equity
Total Liabilities and Shareholders' Equity	114,456	112,422	106,253	104,035	104,922	104,340